PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for ITP patients: switching drugs after failed treatment
Disease control Not yet recruitingThis study looks at 112 people with immune thrombocytopenia (ITP) whose platelet counts didn't improve after standard treatment with rhTPO. After a two-week break, they will either get a higher dose of rhTPO or switch to a different drug called eltrombopag. The goal is to see whi…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
New hope for kids with ITP: drug combo aims to control bleeding
Disease control Not yet recruitingThis phase 2 trial tests whether adding ianalumab to eltrombopag helps children aged 5 to 17 with primary immune thrombocytopenia (ITP) who didn't improve after steroids. The goal is to see if the combination can raise platelet counts and prevent bleeding. About 36 children will …
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to tame rare bleeding disorder
Disease control Not yet recruitingThis phase 2 study tests whether combining orelabrutinib (a targeted drug) with romiplostim (a platelet booster) can improve platelet counts in adults with chronic immune thrombocytopenia (ITP) who haven't responded well to standard treatments. About 28 participants will receive …
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Triple-Drug combo aims to stop bleeding disorder in its tracks
Disease control Not yet recruitingThis study tests a three-step treatment for adults with severe immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants first get steroids and a platelet-boosting protein in the hospital, then switch to an oral drug (el…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE4 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC